Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 4256519, 12 pages
https://doi.org/10.1155/2017/4256519
Research Article

Potassium Ascorbate with Ribose: Promising Therapeutic Approach for Melanoma Treatment

1Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
2Plants for Human Health Institute, Department of Animal Sciences, North Carolina State University, Kannapolis, NC, USA
3Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
4Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy
5Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
6Department of Life Sciences, University of Siena, Siena, Italy

Correspondence should be addressed to Giuseppe Valacchi; ti.efinu@ihccalav.eppesuig

Received 20 May 2017; Accepted 10 July 2017; Published 24 September 2017

Academic Editor: Jean-Claude Lavoie

Copyright © 2017 Carlotta Cavicchio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Manzano, L. Layos, C. Bugés et al., “Resistant mechanisms to BRAF inhibitors in melanoma,” Annals of Translational Medicine, vol. 4, no. 12, p. 237, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. R. L. Siegel, K. D. Miller, and A. C. A. Jemal, “Cancer statistics, 2016,” Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Kakavand, E. Walker, T. Lum et al., “BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting,” Histopathology, vol. 69, no. 4, pp. 680–686, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Loria and E. Matos, “Risk factors for cutaneous melanoma: a case-control study in Argentina,” International Journal of Dermatology, vol. 40, no. 2, pp. 108–114, 2001. View at Publisher · View at Google Scholar
  5. Y. Kamenisch, T. S. A. Baban, W. Schuller et al., “UVA-irradiation induces melanoma invasion via enhanced Warburg effect,” The Journal of Investigative Dermatology, vol. 136, no. 9, pp. 1866–1875, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. J. E. Moan, Z. Baturaite, A. Dahlback, and A. C. Porojnicu, “Ultraviolet radiation and cutaneous malignant melanoma,” Advances in Experimental Medicine and Biology, vol. 810, pp. 359–374, 2014. View at Publisher · View at Google Scholar
  7. C. Garbe, K. Peris, A. Hauschild et al., “Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline,” European Journal of Cancer, vol. 63, pp. 201–217, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Rozati, L. Naef, M. P. Levesque, L. E. French, and R. Dummer, “Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy,” Journal of Immunotherapy, vol. 36, no. 1, pp. 52–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Hauschild, “Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?” Current Oncology, vol. 16, no. 3, pp. 3–6, 2009. View at Publisher · View at Google Scholar
  10. M. S. Sabel and V. K. Sondak, “Pros and cons of adjuvant interferon in the treatment of melanoma,” The Oncologist, vol. 8, no. 5, pp. 451–458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Du, J. J. Cullen, and G. R. Buettner, “Ascorbic acid: chemistry, biology and the treatment of cancer,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1826, no. 2, pp. 443–457, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Paoli, “The biomagnetic nature of cancer and the role of potassium ascorbate and ribose against cellular degeneration,” Journal of New Energy, vol. 7, no. 3, pp. 114–119, 2003. View at Google Scholar
  13. C. Anichini, C. Lo Rizzo, M. Longini et al., “Beckwith-Wiedemann syndrome: potassium ascorbate with ribose therapy in a syndrome with high neoplastic risk,” Anticancer Research, vol. 31, no. 11, pp. 3973–3976, 2011. View at Google Scholar
  14. C. Anichini, F. Lotti, M. Longini et al., “Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi syndrome,” Disease Markers, vol. 33, no. 4, pp. 179–183, 2012. View at Publisher · View at Google Scholar
  15. C. Anichini, F. Lotti, A. Pietrini et al., “Antioxidant effects of potassium ascorbate with ribose in Costello syndrome,” Anticancer Research, vol. 33, no. 2, pp. 691–695, 2013. View at Google Scholar
  16. S. Croci, G. Pedrozzi, G. Paoli, D. Monetti, G. Bronzetti, and I. Ortalli, “Potassium ascorbate as protective agent in oxidation of red cells,” in Abstract of the International Conference on Antioxidants in Cancer Prevention and Therapy, Atene, 2001.
  17. C. Jacobs, B. Hutton, T. Ng, R. Shorr, and M. Clemons, “Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review,” The Oncologist, vol. 20, pp. 210–223, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. H. B. Pollard, M. A. Levine, O. Eidelman, and M. Pollard, “Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastates in hormone-refractory prostate cancer,” In Vivo, vol. 24, no. 3, pp. 249–255, 2010. View at Google Scholar
  19. Y. Takemura, K. Satoh, H. Hamada, Y. Sekido, and S. Kubiota, “High dose of ascorbic acid induces cell death in mesothelioma cells,” Biochemical and Biophysical Research Communications, vol. 394, no. 2, pp. 249–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. G. V. Frajese, M. Benvenuto, M. Fantini et al., “Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines in vitro,” Oncology Letters, vol. 11, pp. 4224–4234, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Cha, M. W. Roomi, V. Ivanov, T. Kalinovsky, A. Niedzwiecki, and M. Rath, “Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice,” International Journal of Oncology, vol. 42, no. 1, pp. 55–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. E. Kim, H. S. Cho, H. S. Yang et al., “Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model,” Immunobiology, vol. 217, no. 9, pp. 873–881, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Della Croce, G. Poi, L. Caltavuturo, M. Badi, G. Paoli, and G. Bronzetti, “Protective effect of potassium ascorbate in different strains of yeasts Saccharomyces cerevisiae,” in VIIIth International Conference on Mechanism of Antimutagenesis and Anticarcinogenesis, B. Giorgio, R. Ferguson Linette, and D. F. Silvio, Eds., Pisa, 2003.
  24. F. Cervellati, X. M. Muresan, C. Sticozzi et al., “Comparative effects between electronic and cigarette smoke in human keratinocytes and epithelial lung cells,” Toxicology In Vitro, vol. 28, pp. 999–1005, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Valacchi, C. Sticozzi, I. Zanardi et al., “Ozone mediators effect on “in vitro” scratch wound closure,” Free Radical Research, vol. 50, pp. 1022–1031, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. Q. Chen, M. G. Espey, M. C. Krishna, J. B. Mitchell, C. P. Corpe, and G. R. Buettner, “Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, pp. 13604–13910, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. T. J. King and J. S. Bertram, “Connexins as targets for cancer chemoprevention and chemotherapy,” Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1719, pp. 146–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Cameron and L. Pauling, “Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 73, pp. 3685–3689, 1976. View at Publisher · View at Google Scholar
  29. E. Cameron and L. Pauling, “Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, pp. 4538–4542, 1978. View at Publisher · View at Google Scholar
  30. E. T. Creagan, C. G. Moertel, J. R. O'Fallon et al., “Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial,” The New England Journal of Medicine, vol. 301, pp. 687–690, 1979. View at Publisher · View at Google Scholar
  31. C. G. Moertel, T. R. Fleming, E. T. Creagan, J. Rubin, M. J. O'Connell, and M. M. Ames, “High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison,” The New England Journal of Medicine, vol. 312, pp. 137–141, 1985. View at Publisher · View at Google Scholar
  32. J. Yun, E. Mullarky, C. Lu et al., “Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH,” Science, vol. 350, no. 6266, pp. 1391–1396, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. U. Gröber, P. Holzhauer, K. Kisters, M. F. Holick, and I. A. Adamietz, “Micronutrients in oncological intervention,” Nutrients, vol. 8, no. 3, p. 163, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. N. K. Haass, D. Ripperger, E. Wladykowski et al., “Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment,” Histochemistry and Cell Biology, vol. 133, pp. 113–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Ableser, S. Penuela, J. Lee, Q. Shao, and D. W. Laird, “Connexin43 reduces melanoma growth within a keratinocyte microenvironment and during tumorigenesis in vivo,” The Journal of Biological Chemistry, vol. 289, no. 3, pp. 1592–1603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Tittarelli, I. Guerrero, F. Tempio et al., “Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity,” British Journal of Cancer, vol. 113, no. 2, pp. 259–267, 2015. View at Publisher · View at Google Scholar · View at Scopus